Holen Sie sich die Stockscreener-App
53.86
1.36%
-0.74
Handel nachbörslich:
53.86
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Inside Wisconsin: Cancer tests continue to propel Exact Sciences, even in a skeptical age - hngnews.com
Tom Still: Cancer tests continue to propel Exact Sciences, even in time of research cuts - La Crosse Tribune
Insider Sell: Katherine Zanotti Sells Shares of Exact Sciences Corp (EXAS) - GuruFocus
Exact Sciences Shareholders Approve New Incentive Plan By Investing.com - Investing.com Canada
Exact Sciences Shareholders Approve New Incentive Plan - Investing.com
Exact Sciences Corp (EXAS) Shares Gap Down to $53.95 on Jun 12 - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Colorectal Cancer Screening Market Deep Research Report - openPR.com
Rhumbline Advisers Acquires 3,873 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Hologic Climbs 13% in a Month: How Should You Play the Stock? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Stock Position Increased by GAMMA Investing LLC - Defense World
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? - Yahoo Finance
Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029 - The Malaysian Reserve
Corporate Wellness News from PRNEWSWIRE - Corporate Wellness Magazine
Exact Sciences at William Blair Conference: Vision for Cancer Eradication - Investing.com
Transcript : Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08 - marketscreener.com
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating - inkl
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap - marketscreener.com
Exact Sciences to present new positive data on Oncodetect in colorectal cancer - TipRanks
Exact Sciences (EXAS) Unveils Advanced MRD Test Data for Colorectal Cancer | EXAS Stock News - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Onc - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap | EXAS Stock News - GuruFocus
Exact Sciences management to meet with Oppenheimer - TipRanks
Upcoming Meeting for Investors with Oppenheimer Highlights EXAS | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference - New Castle News
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Highlights Innovations in Early Cancer Detection - GuruFocus
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
WisBusiness: the Show with Kevin Boggs of Medical College of Wisconsin - WisBusiness
Exact Sciences Corporation (EXAS) Slid on Fear of Competition - Insider Monkey
Comerica Bank Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion - Yahoo Finance
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $75.00 - Defense World
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
1.52%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):